Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | PDE5A | O76074 | 1/20 | 0.73 |
| ▸ | PDE9A | O76083 | 1/20 | 0.73 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.73 |
| ▸ | GYS2 | P54840 | 1/20 | 0.69 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24433072 | 1.00 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL12181490 | 1.00 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL29649785 | 1.00 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL24433073 | 1.00 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL12181496 | 1.00 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL15163880 | 0.95 | PDE4D (0.68) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL15163884 | 0.95 | PDE4D (0.68) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL30925714 | 0.90 | GYS2 (0.85) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL13487369 | 0.89 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BHSD11B1 | |
| SCHEMBL13487370 | 0.89 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151970-A1 | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LU) | 2022-05-19 | — | — | US | claimed |
| US-12605351-B2 | Method for producing a composition comprising a 3-O-p-coumaroyl ester of tormentic acid from a plant cell culture, applications thereof as antiparasitic agent for the treatment of trypanosomiasis | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LU) | 2026-04-21 | — | — | US | disclosed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| US-20220151970-A1 | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LU) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151970-A1 | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS | ME3, ME1, CYP51A1 | PDE4D 3648/4885PDE5A 3859/4885PDE9A 3617/4885 |
| US-12605351-B2 | Method for producing a composition comprising a 3-O-p-coumaroyl ester of tormentic acid from a plant cell culture, applications thereof as antiparasitic agent for the treatment of trypanosomiasis | NFATC1, CYP51A1, ME1 | PDE4D 3852/4885PDE5A 3648/4885PDE9A 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.